Stifel analyst David Grossman raised the firm’s price target on Amwell (AMWL) to $10 from $9 and keeps a Hold rating on the shares. 2025 guidance implies adjusted revenue growth of 8%-12% ex-APC divestiture and lower operating losses, notes the analyst, who is rolling forward the firm’s price target to 2026 estimates.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMWL:
- Strong Revenue Performance and Strategic Growth: Justifying the Buy Rating for American Well
- Hold Rating for American Well Amid Mixed Financial Outlook and Strategic Shifts
- Amwell Reports Improved 2024 Financial Results
- American Well: Navigating Challenges with Resilience and Future Growth Potential
- Amwell sees Q1 revenue $59M-$61M, consensus $74.31M